مستوى عامل تنشيط الخلايا البائية في الدورة الدموية (BAFF) لمرضى ورم النقي المتعدد في حالة انتكاس المرضمقارنة مع المرضى في حالة الإبراء

1. Giannakoulas N, Ntanasis-Stathopoulos I, Terpos E. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma. Int J Mol Sci. 2021 Apr 24;22(9):4462. https://doi.org/10.3390/ijms22094462. DOI: https://doi.org/10.3390/ijms22094462

2. Ahmed A, Killeen RB. Relapsed and Refractory Multiple Myeloma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available from: https://pubmed.ncbi.nlm.nih.gov/37276320/

3. Fragioudaki M, Boula A, Tsirakis G, Psarakis F, Spanoudakis M, Papadakis IS et al. B cell-activating factor: its clinical significance in multiple myeloma patients. Ann Hematol. 2012;91(9):1413–8.

https://doi.org/10.1007/s00277-012-1470-x DOI: https://doi.org/10.1007/s00277-012-1470-x

4. Aziz K, Munjal K, Howe K, Yarchoan M. Mechanisms of B-Cell Activity in Tumor Microenvironment. International Journal of Radiation Oncology, Biology, Physics. 2024;120(2): e352-3. https://doi.org/10.1016/j.ijrobp.2024.07.776 DOI: https://doi.org/10.1016/j.ijrobp.2024.07.776

5. Nobari ST, Nojadeh JN, Talebi M. B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages. J Transl Med 2022;20(1):82. https://doi.org/10.1186/s12967-022-03285-y. DOI: https://doi.org/10.1186/s12967-022-03285-y

6. Lemancewicz D, Bolkun L, Jablonska E, Kulczynska A, Bolkun-Skornicka U, Kloczko J, et al. Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features. Leuk Res. 2013;37(9):1089–93.

https://doi.org/10.1016/j.leukres.2013.05.014 DOI: https://doi.org/10.1016/j.leukres.2013.05.014

7. Tagami N, Yuda J, Goto Y. Current status of BAFF targeting immunotherapy in B-cell neoplasm. Int J Clin Oncol 2024;29:1676-83. https://doi.org/10.1007/s10147-024-02611-2 DOI: https://doi.org/10.1007/s10147-024-02611-2

8. Zhang T, Lin Z, Zheng Z, Wang Q, Zhou S, Zhang B, et al. Prognostic significance of β2-microglobulin decline index in multiple myeloma. Front Oncol. 2024;14:1322680. https://doi.org/10.3389/fonc.2024.1322680. DOI: https://doi.org/10.3389/fonc.2024.1322680

9. Salman AS, Saleh ES, Abass MS. Estimation of beta two microglobulins, fetuin-a, resistin serum levels in Iraqi multiple myeloma patients. Iraqi J Pharm Sci 2020;29(2):80-7. https://doi.org/10.31351/vol29iss2pp80-87 DOI: https://doi.org/10.31351/vol29iss2pp80-87

10. Mielnik M, Szudy-Szczyrek A, Homa-Mlak I, Mlak R, Podgajna-Mielnik M, Gorący A, et al. The Clinical Relevance of Selected Cytokines in Newly Diagnosed Multiple Myeloma Patients. Biomedicines 2023;11(11):3012.

https://doi.org/10.3390/biomedicines11113012 DOI: https://doi.org/10.3390/biomedicines11113012

11. Bębnowska D, Hrynkiewicz R, Grywalska E, Pasiarski M, Sosnowska-Pasiarska B, Smarz-Widelska, et al. Immunological Prognostic Factors in Multiple Myeloma. International Journal of Molecular Sciences 2021;22(7):3587. https://doi.org/10.3390/ijms22073587 DOI: https://doi.org/10.3390/ijms22073587

12. Ramasamy K, Lonial S. Multiple myeloma. In: Hoffbrand AV, Mead AJ, Laffan MA, Collins GP, Hay D (eds.) Hoffbrand's Postgraduate Haematology. 8th ed. Bognor Regis, West Sussex, England: John Wiley & Sons Ltd; 2025. p.524-46.

https://content.e-bookshelf.de/media/reading/L-26506671-7e970491bf.pdf

13. International Myeloma Foundation. International Staging System (ISS) and Revised ISS (R-ISS). Last Medical Content Review: August 24, 2021. Available from:

https://www.myeloma.org/international-staging-system-iss-reivised-iss-r-iss

14. Baiee NH, Al-Rubaie HA. Plasma sclerostin level in multiple myeloma: Correlations with disease features and international staging system. Med J Babylon 2022;19(4):534–9. https://doi.org/10.4103/MJBL.MJBL_99_22 DOI: https://doi.org/10.4103/MJBL.MJBL_99_22

15. Salih ZM, Al-Rubaie HA. Evaluation of angiopoietin-2 level in patients with multiple myeloma at presentation and in remission state. Iraqi Journal of Hematology 2023;12(1):8-12. https://doi.org/10.4103/ijh.ijh_23_23 DOI: https://doi.org/10.4103/ijh.ijh_23_23

16. Pan J, Sun Y, Zhang N, Li J, Ta F, Wei W, et al. Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance. Oncol Lett. 2017;14(3):2657–62. https://doi.org/10.3892/ol.2017.6528 DOI: https://doi.org/10.3892/ol.2017.6528

17. Jasrotia S, Gupta R, Sharma A, Halder A, Kumar L. Cytokine profile in multiple myeloma. Cytokine 2020;136:155271. https://doi.org/10.1016/j.cyto.2020.155271 DOI: https://doi.org/10.1016/j.cyto.2020.155271

18. Jasrotia S, Kumar L, Gupta R. Serum cytokine levels in patients of multiple myeloma at diagnosis and at relapse. Clinical Lymphoma, Myeloma and Leukemia. 2015;15:e252. https://doi.org/10.1016/j.clml.2015.07.535 DOI: https://doi.org/10.1016/j.clml.2015.07.535

19. Wang SM, Zhang TL, Jiang YM, Wu HY, Hao LM, Xing XH. Expression and significance of B cell-activating factor of TNF family (BAFF) and B cell lymphoma/leukemia-2 (BCL-2) in multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011;19(2):395-8. Available from: https://pubmed.ncbi.nlm.nih.gov/21518495/

20. Bolkun L, Lemancewicz D, Jablonska E, Kulczynska A, Bolkun-Skornicka U, Kloczko J, et al. BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma. Ann Hematol. 2014;93(4):635–44. https://doi.org/10.1007/s00277-013-1924-9 DOI: https://doi.org/10.1007/s00277-013-1924-9

21. Alexandrakis MG, Roussou P, Pappa CA, Xekalou A, Goulidaki N, Boula A, et al. Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myeloma. BioMed Research International 2013;2013:389579.

https://doi.org/10.1155/2013/389579 DOI: https://doi.org/10.1155/2013/389579

22. Sayed M, Mohammed MA, Khorshid O. Clinical evaluation of some biochemical markers in multiple myeloma among Egyptian patients. Journal of Medical Sciences 2007;7(6):942–51. https://doi.org/10.3923/jms.2007.942.951 DOI: https://doi.org/10.3923/jms.2007.942.951

23. Garewal H, Durie BG, Kyle RA, Bower B, Serokman R. Serum beta2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. J Clin Oncol. 1984;2(1):51–7. https://doi.org/10.1200/JCO.1984.2.1.51 DOI: https://doi.org/10.1200/JCO.1984.2.1.51

24. Brenning G, Wibell L, Bergstrom R. Serum β2‐microglobulin at remission and relapse in patients with multiple myeloma. Eur J Clin Invest. 1985;15(5):242-7. https://doi.org/10.1111/j.1365-2362.1985.tb00177.x DOI: https://doi.org/10.1111/j.1365-2362.1985.tb00177.x

25. Kyrstsonis MC, Dedou ssis G, Bax evanis C, Stamate lou M, Maniatis A. Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM). Br J Haematol. 1996;92(2):420-22.

https://doi.org/10.1046/j.1365-2141.1996.d01-1491.x DOI: https://doi.org/10.1046/j.1365-2141.1996.d01-1491.x

26. Jiang P, Yueguo W, Huiming H, Hongxiang Y, Mei W, Ju S. B-lymphocyte stimulator: a new biomarker for multiple myeloma. Eur J Haematol. 2009;82(4):267–76.

https://doi.org/10.1111/j.1600-0609.2008.01203.x DOI: https://doi.org/10.1111/j.1600-0609.2008.01203.x